Cabaletta falls on disappointing early-stage data on lead drug

Cabaletta Bio

12/09/2022 17:25

** Cabaletta Bio's shares  CABA.O  fall 4.5% to $0.90
    ** On Saturday, co presented interim data from early-stage
trial of lead drug DSG3-CAART to treat a blistering skin disease
that affects the mucous membranes  urn:newsml:reuters.com:*:nGNX5Wymlb
    ** Brokerage Cowen and Co says while safety data was good,
there were no clear efficacy trends
    ** Results from one subject in one of the subgroups showed
signs of drug efficacy, which may provide optimism - Cowen
    ** 6 of 7 brokerages rate the stock "buy", 1 "hold"; their
median PT is $12
    ** Including session's loss, stock down 76% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))